Schering-Plough’s Fred Hassan: An Interview With “The Pink Sheet”
After unveiling Schering-Plough's R&D pipeline in November, CEO Fred Hassan talked with "The Pink Sheet" in mid-December about balancing primary and specialty care portfolios, fixed-term limits for future FDA commissioners, licensing opportunities and more.
You may also be interested in...
Agency says there is no need for additional clinical trials for the atypical antipsychotic.
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.